This study is in progress, not accepting new patients
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Summary
- Eligibility
- for people ages 18-200 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Zev Wainberg
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Zev Wainberg
HS Clinical Professor, Medicine. Authored (or co-authored) 161 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT04592913
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 957 people participating
- Last Updated